Onc Now
In this episode of Onc Now, Neel Pasricha, a renowned expert in the field of ophthalmology, spotlights the increasingly important intersection between ophthalmology and oncology. As antibody–drug conjugates (ADC) transform cancer treatment, ocular toxicity is emerging as an important clinical challenge, requiring closer collaboration between cancer specialists and eye care professionals. Drawing on his clinical and research expertise, Pasricha explores what we know about treatment-related ocular toxicity, how clinicians can better monitor patients receiving ADCs, and why standardised reporting and interdisciplinary collaboration could be key to improving care.
Speaker bio:
Neel Pasricha is the Assistant Professor for Ophthalmology at the University of California San Francisco, USA. His clinical expertise includes cataract surgery, corneal transplantation, and ocular surface surgery, while his research focuses on developing new approaches to prevent and manage ocular toxicity associated with cancer treatments, including antibody–drug conjugates.
Timestamps:
00:00 – Introduction
01:03 – Clinical and research interests
02:40 – Ocular toxicity from ADCs
04:24 – Managing ocular toxicity clinically
05:47 – Standardising ocular adverse event reporting
09:12 – Ophthalmology-oncology collaboration
11:40 – Ocular surface and dry eye
13:55 – Future of ocular toxicity
15:58 – Three wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Disclosure: Pasricha has received grants or contracts from Alcon and Johnson & Johnson; consulting fees from 2A Biosciences, AbbVie, Amgen, ArriVent BioPharma, AstraZeneca, Daiichi Sankyo, Denali, Glaukos, GlaxoSmithKline, Hexagon Bio, Iksuda Therapeutics, LigaChem Biosciences, Sanofi, Vanda Pharmaceuticals, and Zeiss; and holds stock or stock options in Diatiro and Globe Biomedical.
